Seres Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Seres Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $789.0K | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $0 | Mar 12, 2026 |
| FY2023 | Dec 31, 2022 | $7.13M | Mar 5, 2024 |
| FY2023 | Dec 31, 2021 | $144.93M | Mar 5, 2024 |
| FY2022 | Dec 31, 2020 | $33.22M | Mar 7, 2023 |
| FY2021 | Dec 31, 2019 | $34.51M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $28.27M | Mar 2, 2021 |
| FY2019 | Dec 31, 2017 | $32.10M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $21.77M | Mar 6, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $7.13M | Mar 7, 2023 |
| FY2022 | Dec 31, 2021 | $143.86M | Mar 7, 2023 |
| FY2022 | Dec 31, 2020 | $11.90M | Mar 7, 2023 |
| FY2021 | Dec 31, 2019 | $27.19M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $26.92M | Mar 2, 2021 |
| FY2019 | Dec 31, 2017 | $32.10M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $21.77M | Mar 6, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.70M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $136.0K | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | ($113.72M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | ($250.16M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | ($65.58M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2020 | ($89.13M) | Mar 7, 2023 |
| FY2019 | Dec 31, 2019 | ($18.78M) | Mar 2, 2020 |
| FY2019 | Sep 30, 2019 | ($16.41M) | Mar 2, 2020 |
| FY2019 | Jun 30, 2019 | ($10.76M) | Mar 2, 2020 |
| FY2019 | Mar 31, 2019 | ($24.33M) | Mar 2, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($93.97M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($121.32M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | ($195.10M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | ($179.91M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | ($64.49M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2020 | ($88.13M) | Mar 7, 2023 |
| FY2019 | Dec 31, 2019 | ($19.19M) | Mar 2, 2020 |
| FY2019 | Sep 30, 2019 | ($17.18M) | Mar 2, 2020 |
| FY2019 | Jun 30, 2019 | ($10.95M) | Mar 2, 2020 |
| FY2019 | Mar 31, 2019 | ($24.55M) | Mar 2, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $49.06M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $64.60M | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $117.60M | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $109.65M | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | $141.89M | Mar 5, 2024 |
| FY2022 | Dec 31, 2020 | $90.57M | Mar 7, 2023 |
| FY2021 | Dec 31, 2019 | $80.14M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $95.96M | Mar 2, 2021 |
| FY2019 | Dec 31, 2017 | $89.46M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $81.99M | Mar 6, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.12M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($148.61M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | ($117.35M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | ($228.82M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | $6.69M | Mar 5, 2024 |
| FY2022 | Dec 31, 2020 | ($93.61M) | Mar 7, 2023 |
| FY2021 | Dec 31, 2019 | ($76.52M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | ($62.85M) | Mar 2, 2021 |
| FY2019 | Dec 31, 2017 | ($75.52M) | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $43.92M | Mar 6, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $252.0K | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $380.0K | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $7.98M | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $9.82M | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | $9.57M | Mar 5, 2024 |
| FY2022 | Dec 31, 2020 | $591.0K | Mar 7, 2023 |
| FY2021 | Dec 31, 2019 | $1.00M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $1.94M | Mar 2, 2021 |
| FY2019 | Dec 31, 2017 | $4.68M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $21.49M | Mar 6, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $138.19M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $139.81M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $358.60M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $348.78M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $354.86M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | $342.94M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $132.44M | Mar 2, 2021 |
| FY2019 | Dec 31, 2018 | $120.47M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $189.52M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $272.65M | Mar 8, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $93.98M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $126.03M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $403.46M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $338.00M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $223.35M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | $168.19M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $180.76M | Mar 2, 2021 |
| FY2019 | Dec 31, 2018 | $168.52M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $128.82M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $140.02M | Mar 8, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $44.22M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $13.78M | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | ($44.86M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2022 | $10.78M | Mar 12, 2026 |
| FY2024 | Dec 31, 2021 | $131.51M | Mar 13, 2025 |
| FY2023 | Dec 31, 2020 | $174.75M | Mar 5, 2024 |
| FY2022 | Dec 31, 2019 | ($48.32M) | Mar 7, 2023 |
| FY2021 | Dec 31, 2018 | ($48.05M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2017 | $60.70M | Mar 2, 2021 |
| FY2019 | Dec 31, 2016 | $132.63M | Mar 2, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($972.40M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($978.10M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($978.24M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($864.51M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($614.35M) | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | ($548.78M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($459.65M) | Mar 2, 2021 |
| FY2019 | Dec 31, 2018 | ($389.37M) | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | ($263.57M) | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | ($174.19M) | Mar 8, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $45.77M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $30.79M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $127.97M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $163.03M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $180.00M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | $116.05M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $65.13M | Mar 2, 2021 |
| FY2019 | Dec 31, 2018 | $85.82M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $36.09M | Mar 6, 2019 |
| FY2018 | Dec 31, 2016 | $54.54M | Mar 6, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $110.00M | Mar 5, 2024 |
| FY2022 | Dec 31, 2022 | $50.00M | Mar 7, 2023 |
| FY2021 | Dec 31, 2021 | $24.05M | Mar 1, 2022 |
| FY2020 | Dec 31, 2020 | $25.00M | Mar 2, 2021 |
| FY2019 | Dec 31, 2019 | $25.00M | Mar 2, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | (17) | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | (2) | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Mar 5, 2024 |
| FY2022 | Dec 31, 2020 | (1) | Mar 7, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | (17) | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | (2) | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Mar 5, 2024 |
| FY2022 | Dec 31, 2020 | (1) | Mar 7, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 9.56M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | 8.65M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | 135.04M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | 125.22M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | 91.89M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | 91.46M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | 70.14M | Mar 2, 2021 |
| FY2019 | Dec 31, 2018 | 40.94M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | 40.57M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | 40.36M | Mar 8, 2018 |